1[1]Warsaw K,Fedorova N, Takats A, et al .A multicenter trial of piribedil as early adjunct treatment for Parkinson's disease: piribedil international study group (PISG)[J]. Neurology, 2002 ; 58(Suppl 3): 163.
2[2]Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial [J]. JAMA, 2000; 284(15):1931-8.
4[4]Jenner P. Pharmacology of dopamine agonist in the treatment of Parkinson's disease[J]. Neurology,2002; 58 (Suppl 1):1-8.
5[5]Lebrun-Frenay C, Borg M. Choosing the right dopamine agonist for patients with Parkinson's disease[J]. Curr Med Res Opin,2002;18(4):209-14.
6[6]Stocchi F, Ruggieri S, Vacca L, et al . Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease[J]. Brain,2002;125:2058-66.
7[7]Goetz CG, Leurgans S, Pappert EJ, et al . Prospective longitudinal assessment of hallucinations in Parkinson's disease[J]. Neurology,2002;57(11):2078-82.
8[8]Cantor CR, Stern MB. Dopamine agonists and sleep in Parkinson's disease[J]. Neurology,2002; 58(Suppl 1):71-8.
9[9]Homann CN, Wenzel K, Suppan K, et al . Sleep attracts in patients taking dopamine agonist[J]. BMJ,2002; 324:1483-7.
10[10]Schlesinger I, Ravin PD. Dopamine agonists induce episodes of irresistible daytime sleepiness[J].Eur Neurol (Basel),2003;49(1):30-7.
